{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:19:54Z","timestamp":1790266794577,"version":"4.1.0"},"reference-count":51,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":199,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the diagnostic test accuracy of Afirma GSC and ThyroSeq v3 in cytologically indeterminate thyroid nodules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Cochrane Library, Medline, and the Web of Science were searched from the date of inception to May 9, 2025. Two independent reviewers screened articles for eligibility. Studies assessing Afirma gene sequencing classifier (GSC) or ThyroSeq v3 for indeterminate thyroid nodules were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis reporting guidelines were followed. Statistical analysis was performed using R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 26 studies met the eligibility criteria. For surgically confirmed Afirma GSC results, the sensitivity, specificity, and negative predictive value (NPV) were 94, 42, and 96%, respectively. For unoperated negative cases, the values were 96, 86, and 99%. For ThyroSeq v3, the sensitivity, specificity, and NPV for surgically confirmed cases were 96, 40, and 93%, respectively, and for unoperated negative cases, they were 97, 83, and 99%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both molecular tests demonstrate high NPV but low specificity; neither is clearly superior. Future research should prioritise randomised controlled trials, long-term follow-up of unoperated nodules, and direct comparisons of molecular tests.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0296","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:46:30Z","timestamp":1764600390000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":7,"title":["Comparing the diagnostic accuracy of Afirma GSC to ThyroSeq V3 in cytologically indeterminate thyroid nodules"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3289-1656","authenticated-orcid":true,"given":"Natasha","family":"Dowell","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6060-3726","authenticated-orcid":true,"given":"Shayma","family":"Begum","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-0269","authenticated-orcid":true,"given":"Jameel","family":"Muzaffar","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-177X","authenticated-orcid":true,"given":"Kristien","family":"Boelaert","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3088-7848","authenticated-orcid":true,"given":"Hannah","family":"Nieto","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026070714004742100_bib1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.beem.2008.09.019","article-title":"Epidemiology of thyroid nodules","volume":"22","author":"Dean","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070714004742100_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/jc.2012-2968","article-title":"Thyroid nodule size and prediction of cancer","volume":"98","author":"Kamran","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714004742100_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.sult.2011.12.002","article-title":"Thyroid nodule fine-needle aspiration","volume":"33","author":"Langer","year":"2012","journal-title":"Seminars Ultrasound CT MRI"},{"key":"2026070714004742100_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000339959","article-title":"The Bethesda system for reporting thyroid cytopathology: a meta-analysis","volume":"56","author":"Bongiovanni","year":"2012","journal-title":"Acta Cytol"},{"key":"2026070714004742100_bib5","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1210\/clinem\/dgad181","article-title":"Bethesda III and IV thyroid nodules managed nonoperatively after molecular testing with Afirma GSC or Thyroseq v3","volume":"108","author":"Kim","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714004742100_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1308\/rcsann.2022.0163","article-title":"Indeterminate thyroid nodules (Thy3): malignancy rate and characteristics in a study of 118 patients","volume":"105","author":"Dimitriadis","year":"2023","journal-title":"Ann R Coll Surg Engl"},{"key":"2026070714004742100_bib7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/thy.2014.0502","article-title":"American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making","volume":"25","author":"Ferris","year":"2015","journal-title":"Thyroid"},{"key":"2026070714004742100_bib8","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1210\/clinem\/dgab304","article-title":"Afirma genomic sequencing classifier and xpression atlas molecular findings in consecutive Bethesda III\u2013VI thyroid nodules","volume":"106","author":"Hu","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714004742100_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070714004742100_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cncy.22332","article-title":"Diagnostic performances of the Afirma gene sequencing classifier in comparison with the gene expression classifier: a meta-analysis","volume":"129","author":"Vuong","year":"2020","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib11","doi-asserted-by":"crossref","first-page":"A745","DOI":"10.1210\/jendso\/bvac150.1538","article-title":"Real world performance of the Afirma genomic sequencing classifier (GSC) \u2013 a meta-analysis","volume":"6","author":"Nasr","year":"2022","journal-title":"J Endocr Soc"},{"key":"2026070714004742100_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12022-019-9566-7","article-title":"Correction to: evaluation of 167 gene expression classifier (GEC) and ThyroSeq v2 diagnostic accuracy in the preoperative assessment of indeterminate thyroid nodules: bivariate\/hroc meta-analysis","volume":"30","author":"Borowczyk","year":"2019","journal-title":"Endocr Pathol"},{"key":"2026070714004742100_bib13","first-page":"1","article-title":"The diagnostic performance of Afirma gene expression classifier for the indeterminate thyroid nodules: a meta-analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"Biomed Res Int"},{"key":"2026070714004742100_bib14","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1530\/ERC-17-0405","article-title":"Genetic testing for indeterminate thyroid cytology: review and meta-analysis","volume":"25","author":"Vargas-Salas","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026070714004742100_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649522","article-title":"Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis","volume":"12","author":"Silaghi","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070714004742100_bib16","doi-asserted-by":"crossref","first-page":"103394","DOI":"10.1016\/j.amjoto.2022.103394","article-title":"Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: a systematic review and meta-analysis","volume":"43","author":"Lee","year":"2022","journal-title":"Am J Otolaryngol"},{"key":"2026070714004742100_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026070714004742100_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"2026070714004742100_bib19","volume-title":"R: The R Project for Statistical Computing [Internet]","author":"R Core Team","year":"2022"},{"key":"2026070714004742100_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Base Ment Health"},{"key":"2026070714004742100_bib21","article-title":"Mada: meta-analysis of diagnostic accuracy","volume-title":"R Package Version 0.5.11, [Internet]","author":"Sousa-Pinto","year":"2022"},{"key":"2026070714004742100_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"2026070714004742100_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinforma"},{"key":"2026070714004742100_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"key":"2026070714004742100_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"},{"key":"2026070714004742100_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamaoncol.2020.5935","article-title":"Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules","volume":"7","author":"Livhits","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026070714004742100_bib27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0726","article-title":"Independent comparison of the Afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate thyroid nodules","volume":"29","author":"Angell","year":"2019","journal-title":"Thyroid"},{"key":"2026070714004742100_bib28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1089\/thy.2018.0733","article-title":"Afirma gene sequencing classifier compared with gene expression classifier in indeterminate thyroid nodules","volume":"29","author":"Endo","year":"2019","journal-title":"Thyroid"},{"key":"2026070714004742100_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4158\/EP-2018-0395","article-title":"Statistical comparison of Afirma Gsc and Afirma Gec outcomes in a community endocrine surgical practice: early findings","volume":"25","author":"Harrell","year":"2018","journal-title":"Endocr Pract"},{"key":"2026070714004742100_bib30","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz099","article-title":"Real-world comparison of Afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules","volume":"105","author":"San Martin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714004742100_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/cyt.12920","article-title":"Comparison of Afirma gene expression classifier with gene sequencing classifier in indeterminate thyroid nodules: a single-institutional experience","volume":"32","author":"Geng","year":"2020","journal-title":"Cytopathology"},{"key":"2026070714004742100_bib32","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab148","article-title":"Comparison of Afirma GEC and GSC to nodules without molecular testing in cytologically indeterminate thyroid nodules","volume":"5","author":"Polavarapu","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026070714004742100_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/dc.24765","article-title":"Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: an institutional experience","volume":"49","author":"Zhang","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"2026070714004742100_bib34","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1089\/thy.2020.0801","article-title":"Single institution experience with Afirma and Thyroseq testing in indeterminate thyroid nodules","volume":"31","author":"Gortakowski","year":"2021","journal-title":"Thyroid"},{"key":"2026070714004742100_bib35","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/dc.25203","article-title":"Performance of Afirma genomic sequencing classifier and histopathological outcome in Bethesda category III thyroid nodules: initial versus repeat fine-needle aspiration","volume":"51","author":"Jin","year":"2023","journal-title":"Diagn Cytopathol"},{"key":"2026070714004742100_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/cncy.22625","article-title":"Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules","volume":"130","author":"Jin","year":"2022","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib37","first-page":"458","article-title":"Performance of Afirma gene sequencing classifier versus gene expression classifier in thyroid nodules with indeterminate cytology","volume":"13","author":"Yang","year":"2022","journal-title":"J Am Soc Cytopathology"},{"key":"2026070714004742100_bib38","doi-asserted-by":"crossref","first-page":"e2231","DOI":"10.1210\/clinem\/dgae112","article-title":"Outcomes of cytologically indeterminate thyroid nodules managed with genomic sequencing classifier","volume":"109","author":"Ahmadi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714004742100_bib39","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/hed.27472","article-title":"European experience with the Afirma gene expression classifier for indeterminate thyroid nodules: a clinical utility study in the Netherlands","volume":"45","author":"Lon\u010dar","year":"2023","journal-title":"Head Neck"},{"key":"2026070714004742100_bib40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cncy.22283","article-title":"High-risk and intermediate-high\u2013risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: independent performance assessment at an academic institution","volume":"128","author":"Jug","year":"2020","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/SLA.0000000000004130","article-title":"The clinical utility of molecular testing in the management of thyroid follicular neoplasms (Bethesda IV nodules)","volume":"272","author":"Carty","year":"2020","journal-title":"Ann Surg"},{"key":"2026070714004742100_bib42","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1089\/thy.2019.0539","article-title":"The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the Canadian public health care setting","volume":"30","author":"Chen","year":"2020","journal-title":"Thyroid"},{"key":"2026070714004742100_bib43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cncy.22362","article-title":"ThyroSeq v3 for Bethesda III and IV: an institutional experience","volume":"129","author":"Desai","year":"2020","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncy.22617","article-title":"Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia","volume":"130","author":"Gajzer","year":"2022","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncy.22737","article-title":"Probability of malignancy and molecular alterations as determined by ThyroSeq v3 genomic classifier in Bethesda category IV","volume":"131","author":"Youley","year":"2023","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/dc.25311","article-title":"ThyroSeq overview on indeterminate thyroid nodules: an institutional experience","volume":"52","author":"Sirotnikov","year":"2024","journal-title":"Diagn Cytopathol"},{"key":"2026070714004742100_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cncy.22796","article-title":"Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules","volume":"132","author":"Yang","year":"2024","journal-title":"Cancer Cytopathology"},{"key":"2026070714004742100_bib48","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1210\/clinem\/dgae355","article-title":"Publicly funded molecular testing of indeterminate thyroid nodules: canada\u2019s experience","volume":"110","author":"L\u00e9vesque","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714004742100_bib49","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0170","article-title":"Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis","volume":"13","author":"Vardarli","year":"2024","journal-title":"Endocr Connections"},{"key":"2026070714004742100_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X221083542","article-title":"Long-term Follow-up of cytologically indeterminate thyroid nodules found benign on molecular testing: a validation study","volume":"6","author":"White","year":"2022","journal-title":"OTO Open"},{"key":"2026070714004742100_bib51","doi-asserted-by":"crossref","first-page":"8872","DOI":"10.1245\/s10434-021-10375-6","article-title":"Longitudinal assessment of quality of life following molecular testing for indeterminate thyroid nodules","volume":"28","author":"Schumm","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/6\/ETJ-25-0296.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/6\/ETJ-25-0296.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0296\/506736\/etj-25-0296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0296\/506736\/etj-25-0296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:00Z","timestamp":1783447260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/6\/e250296\/75634\/Comparing-the-diagnostic-accuracy-of-Afirma-GSC-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0296","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"e250296"}}